Clinical trials: Pioglitazone
Diabetes Mellitus, Type 2
Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes
The purpose of the study is to determine the efficacy of alogliptin compared to placebo when given alone or as add-on therapy to metformin or add-on to pioglitazone (with or without metformin).
- Trial name
- NCT01289119
- Testing
- Alogliptin, Metformin, Pioglitazone
- Where
- 21 sites in China, Hong Kong and 1 more
- Volunteers
- 506 people
- Sponsor
- Takeda
Healthy Volunteers
A Study to Determine the Bioequivalence of Alogliptin and Pioglitazone When Administered as Individual Tablets and as Fixed-Dose Combination (FDC)-SYR-322-4833 BL Tablets to Healthy Russian Participants
The purpose of this study is to assess the relative bioavailability and bioequivalence of 2 strengths of the FDC tablet product SYR-322-4833 BL compared to the individual alogliptin and pioglitazone tablets in healthy Russian…
- Trial name
- NCT03501277
- Testing
- Alogliptin, Pioglitazone, SYR-322-4833 BL
- Where
- Russia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Takeda
HIV Lipodystrophy
Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome
The purpose of this study is to determine whether patients with HIV lipodystrophy (fat wasting) benefit from taking the combination of two drugs, one insulin sensitizer (either metformin or pioglitazone, both diabetes drugs) and…
- Trial name
- NCT00362440
- Testing
- Leptin, Pioglitazone or metformin
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Type 2 Diabetes Mellitus
Alogliptin/Pioglitazone (Liovel) Combination Tablets Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus
The purpose of this survey is to examine the safety and efficacy of long-term use of alogliptin/pioglitazone(Liovel) combination tablets in patients with type 2 diabetes mellitus determined as warranting combination therapy with…
- Trial name
- NCT01990300
- Testing
- Alogliptin/Pioglitazone
- Where
- Japan
- Volunteers
- 3,281 people
- Sponsor
- Takeda
Polycystic Ovary Syndrome, Infertility
Ovulation Induction in Women With Clomiphene Citrate Resistant PCOS
Polycystic ovary syndrome (PCOS) affects 5-10% of women in childbearing age. Hyperinsulinemia contributes to chronic anovulation commonly encountered in women with PCOS. The first choice therapy is clomiphene citrate (CC).
- Trial name
- NCT01909141
- Testing
- induction of ovulation using letrozole-pioglitazone-metformin, induction of ovulation using clomiphene citrate-pioglitazone-metformin, transvaginal ultrasound
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Cairo University
Type 2 Diabetes Mellitus
A Post-Marketing Surveillance Study on NesinaAct® Tablet Use Among Type 2 Diabetes Mellitus Participants in Korea
The purpose of this post marketing surveillance (PMS) study is to estimate the proportion of all adverse events (AEs) including serious adverse events (SAEs) and serious adverse drug reactions (SADRs) in participants who are…
- Trial name
- NCT04980014
- Testing
- NesinaAct® Tablet
- Where
- 8 sites in South Korea
- Volunteers
- 730 people
- Sponsor
- Takeda
Fractures, Bone, Type II Diabetes
Fracture Risk With Thiazolidinediones
Treatment with thiazolidinediones (TZD) has recently been reported to possibly increase the risk of fractures in a randomized trial exploring the efficacy of rosiglitazone (RSG), metformin, or glyburide encompassing 4360 patients…
- Trial name
- NCT01055223
- Testing
- TZD only (RSG or PIO or troglitazone), TZD + spironolactone, TZD + amiloride
- Volunteers
- 98,483 people
- Sponsor
- GlaxoSmithKline
Diabetes
A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
The purpose of this trial is to understand if adding saxagliptin to metformin therapy is safe and works better than taking either saxagliptin or metformin alone
- Trial name
- NCT00327015
- Testing
- Saxagliptin, Metformin, pioglitazone
- Where
- 211 sites in United States, Argentina and 11 more
- Volunteers
- 1,306 people
- Sponsor
- AstraZeneca
Heroin Dependence, Nicotine Dependence
Pioglitazone for Heroin and for Nicotine Dependence
The goal of the proposed research is to improve the effectiveness of treatments for opioid and for nicotine dependence by testing a novel pharmacological strategy.
- Trial name
- NCT01395797
- Testing
- PIO
- Where
- United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Diabetes Mellitus, Type 2
A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone
The purpose of this clinical research study is to learn whether Saxagliptin added to thiazolidinedione (TZD) therapy is more effective than TZD alone as a treatment for Type 2 diabetic subjects who are not sufficiently controlled…
- Trial name
- NCT00295633
- Testing
- Saxagliptin, pioglitazone, rosiglitazone
- Where
- 133 sites in United States, Argentina and 6 more
- Volunteers
- 565 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
Adding Sitagliptin or Pioglitazone to Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin and Sulfonylurea
This 24-weeks study will to compare the glycemic efficacy and safety of sitagliptin with pioglitazone in patients with type 2 diabetes who had inadequate glycemic control despite dual therapy with metformin and a sulfonylurea.
- Trial name
- JAS (NCT01195090)
- Testing
- Sitagliptin, pioglitazone
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- Sung-Chen Liu
Fatty Liver
Insulin Resistance in Non-alcoholic Fatty Liver Disease
The study is designed to investigate the relationship between insulin resistance and non-alcoholic fatty liver disease (NAFLD) and to investigate potential mechanisms underlying insulin resistance in NAFLD by determining…
- Trial name
- NCT01289639
- Testing
- fenofibrate, pioglitazone
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Oral Cavity Neoplasm, Oropharyngeal Neoplasm
ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment
This randomized phase IIb trial studies how well ACTOplus met extended release (XR) works in treating in patients with stage I-IV oral cavity or oropharynx cancer that are undergoing definitive treatment.
- Conditions
- Oral Cavity Neoplasm, Oropharyngeal Neoplasm, Stage 0 Oral Cavity Squamous Cell Carcinoma American Joint Committee on Cancer (AJCC) v6 and v7, Stage 0 Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7
- Trial name
- NCT02917629
- Testing
- Laboratory Biomarker Analysis, Metformide Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet, Pharmacological Study
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Metabolic Syndrome
Pioglitazone vs Placebo in Combination With Niacin Extended Release on Low HDL
We will test our primary hypothesis that combining niacin extended release (niacin-ER), at a daily dosage of up to 2.0 g with pioglitazone, at a daily dosage of 45 mg will result in a 12% greater increase in HDL-C when compared…
- Trial name
- NCT00300365
- Testing
- Pioglitazone, Niacin ER, Aspirin
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Pennsylvania
Insulin Sensitivity, Obstructive Sleep Apnea
Obesity, Sleep Apnea, and Insulin Resistance
Obstructive sleep apnea (OSA) and type 2 diabetes confer increasing economic, social, and public health burdens in the United States.
- Trial name
- NCT02192684
- Testing
- Pioglitazone
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Stanford University
HIV Infections, Hepatic Steatosis
Pioglitazone to Treat Fatty Liver in People With HIV Infection
This study will determine whether pioglitazone (Actos, a drug approved to treat diabetes, can benefit HIV-infected people with fatty liver.
- Conditions
- HIV Infections, Hepatic Steatosis, Insulin Resistance
- Trial name
- NCT00441272
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Diabetes
Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM
Type 2 diabetes is a systemic metabolic disease with significant morbidity and mortality due to damaging blood vessels. Increased blood sugar level is a hallmark of diabetes and is an contributes to the development of many of its…
- Trial name
- NCT01107717
- Testing
- metformin\pioglitazone\exenatide, metformin, glyburide and glargine
- Where
- United States
- Volunteers
- 318 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Prediabetic State
DPP-4 Inhibition and TZD for DM Prevention
To determine whether treatment with the diabetes medication, Januvia (sitagliptin), with or without another diabetes medicine, Actos (pioglitazone), will improve insulin secretion and insulin response individuals with Impaired…
- Trial name
- DInT DM (NCT01006018)
- Testing
- Sitagliptin + Pioglitazone
- Where
- 2 sites in United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Emory University
Nonalcoholic Steatohepatitis
Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment
Nonalcoholic fatty liver disease (NAFLD) is a chronic liver condition frequently associated with type 2 diabetes (T2DM) and characterized by insulin resistance and hepatic fat accumulation.
- Trial name
- VA NASH (NCT01002547)
- Testing
- pioglitazone, Vitamin E
- Where
- 2 sites in United States
- Volunteers
- 105 people
- Sponsor
- VA Office of Research and Development
Opioid Abuse
Effects of Pioglitazone, a PPARgamma Receptor Agonist, on the Abuse Liability of Oxycodone
The ability of pioglitazone (PIO) to alter the effects of opioids in humans has not been characterized in a controlled laboratory setting.
- Trial name
- NCT01395784
- Testing
- pioglitazone
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute